Get the Stockscreener App
6.51
2.84%
-0.19
Starling Oncology, Inc. Common Stock Stock (STLN) Forecast
The Starling Oncology, Inc. Common Stock (STLN) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $6.3804, representing a -1.99% decrease from the current price of $6.51. The highest analyst price target is $6.9002, and the lowest is $5.8605.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month STLN Price Target
Average 6.30
(-3.23% Downside)
Is Starling Oncology, Inc. Common Stock (STLN) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 51.74 | Neutral |
| STOCH(9,6) | 53.23 | Neutral |
| STOCHRSI(14) | 37.23 | Neutral |
| MACD(12,26) | 0.0629 | Buy |
| ADX(14) | 34.62 | Buy |
| William %R | -56.00 | Neutral |
| CCI(14) | 18.35 | Neutral |
Buy: 2
Sell: 0
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
6.4815
Buy
|
6.5548
Sell
|
| MA20 |
6.5873
Sell
|
6.5102
Sell
|
| MA50 |
6.3535
Buy
|
6.3339
Buy
|
| MA100 |
3.2285
Buy
|
0.00
Buy
|
| MA200 |
1.6142
Buy
|
0.00
Buy
|
Buy: 7
Sell: 3
Neutral: 0
Summary: Buy
According to our latest analysis, STLN could be considered a Strong Buy, with 17 technical analysis indicators signaling 9 Buy signals, 3 signaling Sell signals and 5 Neutral signals. This might be a good time to open fresh positions on STLN, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 51.74 indicates that STLN is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 53.23 indicates that STLN is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 37.23 indicates that STLN is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 34.62 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 18.35 indicates that STLN is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term STLN price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Starling Oncology, Inc. Common Stock financial reports and earnings history, Starling Oncology, Inc. Common Stock (STLN) stock could reach $8.45 by 2030, $12.45 by 2040 and $16.22 by 2050. See the projected annual prices until 2050 of the Starling Oncology, Inc. Common Stock stock below:
- Starling Oncology, Inc. Common Stock (STLN) is expected to reach an average price of $9.5822 in 2035, with a high prediction of $10.45 and a low estimate of $8.25. This indicates an $47.19% rise from the last recorded price of $6.51.
- Starling Oncology, Inc. Common Stock (STLN) stock is projected to chart a bullish course in 2040, with an average price target of $11.34, representing an $74.13% surge from its current level. The forecast ranges from a conservative $10.25 to a sky-high $12.45.
- Our analysts predict Starling Oncology, Inc. Common Stock (STLN) to jump 105.44% by 2045, soaring from $13.20 to an average price of $13.37, potentially reaching $14.22. While $13.20 is the low estimate, the potential upside is significant.
- Starling Oncology, Inc. Common Stock (STLN) stock is expected to climb by 2050, reaching an average of $15.64, a $140.21% jump from its current level. However, a wide range of estimates exists, with high and low targets of $16.22 and $15.21, respectively, highlighting the market's uncertainty.
Starling Oncology, Inc. Common Stock Stock (STLN) Year by Year Forecast
Starling Oncology, Inc. Common Stock Stock (STLN) Price Forecast for 2026
The predicted value for Starling Oncology, Inc. Common Stock (STLN) in 2026 is set at an average of $6.0404. Estimates vary from a peak of $7.2308 to a trough of $4.85, indicating an -7.21% surge from the present price of $6.51.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| November, 2026 | $6.2707 | $5.8605 | $6.9002 | -3.68% |
| December, 2026 | $6.4512 | $6.2208 | $7.2308 | -0.90% |
Starling Oncology, Inc. Common Stock Stock (STLN) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Starling Oncology, Inc. Common Stock (STLN) is $6.3421, with a high forecast of $7.6342 and a low forecast of $5.05. This indicates an -2.58% decrease from the last price of $6.51.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $6.6502 | $5.05 | $7.25 | +2.15% |
| February, 2027 | $6.1312 | $5.961 | $7.0005 | -5.82% |
| March, 2027 | $6.5524 | $6.0514 | $7.3317 | +0.65% |
| April, 2027 | $6.7504 | $5.15 | $7.35 | +3.69% |
| May, 2027 | $6.4722 | $6.0614 | $7.1007 | -0.58% |
| June, 2027 | $6.6536 | $6.4225 | $7.4325 | +2.21% |
| July, 2027 | $6.8505 | $5.25 | $7.45 | +5.23% |
| August, 2027 | $6.5729 | $6.1619 | $7.201 | +0.97% |
| September, 2027 | $6.7548 | $6.5234 | $7.5334 | +3.76% |
| October, 2027 | $6.9506 | $5.35 | $7.55 | +6.77% |
| November, 2027 | $6.6736 | $6.2624 | $7.3012 | +2.51% |
| December, 2027 | $6.856 | $6.6242 | $7.6342 | +5.31% |
Starling Oncology, Inc. Common Stock Stock (STLN) Price Forecast for 2028
In 2028, Starling Oncology, Inc. Common Stock (STLN) is projected to reach an average price of $6.7438, with a high projection of $8.0376 and a low estimate of $5.45. This indicates an +3.59% rise from the last price of $6.51.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $7.0664 | $5.45 | $7.65 | +8.55% |
| February, 2028 | $6.7743 | $6.3629 | $7.2872 | +4.06% |
| March, 2028 | $6.9572 | $6.725 | $7.735 | +6.87% |
| April, 2028 | $7.1508 | $5.55 | $7.75 | +9.84% |
| May, 2028 | $6.875 | $6.4634 | $7.5017 | +5.61% |
| June, 2028 | $7.0584 | $6.8259 | $7.8359 | +8.42% |
| July, 2028 | $7.2669 | $5.65 | $7.85 | +11.63% |
| August, 2028 | $6.9758 | $6.5638 | $7.4879 | +7.15% |
| September, 2028 | $7.1596 | $6.9267 | $7.9367 | +9.98% |
| October, 2028 | $7.3672 | $5.75 | $7.95 | +13.17% |
| November, 2028 | $7.0765 | $6.6643 | $7.5882 | +8.70% |
| December, 2028 | $7.2608 | $7.0276 | $8.0376 | +11.53% |
Starling Oncology, Inc. Common Stock Stock (STLN) Price Forecast for 2029
The 2029 price forecast for Starling Oncology, Inc. Common Stock Stock (STLN) is $7.1455 on average, with a high prediction of $8.4409 and a low estimate of $5.85. This represents an +9.76% increase from the previous price of $6.51.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $7.4674 | $5.85 | $8.05 | +14.71% |
| February, 2029 | $7.1772 | $6.7648 | $7.6886 | +10.25% |
| March, 2029 | $7.362 | $7.1284 | $8.1384 | +13.09% |
| April, 2029 | $7.5676 | $5.95 | $8.15 | +16.25% |
| May, 2029 | $7.2779 | $6.8653 | $7.789 | +11.80% |
| June, 2029 | $7.4632 | $7.2292 | $8.2392 | +14.64% |
| July, 2029 | $7.6679 | $6.05 | $8.25 | +17.79% |
| August, 2029 | $7.3786 | $6.9658 | $7.8893 | +13.34% |
| September, 2029 | $7.5644 | $7.3301 | $8.3401 | +16.20% |
| October, 2029 | $7.7681 | $6.15 | $8.35 | +19.33% |
| November, 2029 | $7.4794 | $7.0662 | $7.9897 | +14.89% |
| December, 2029 | $7.9472 | $7.4309 | $8.4409 | +22.08% |
Starling Oncology, Inc. Common Stock Stock (STLN) Price Forecast for 2030
Starling Oncology, Inc. Common Stock Stock (STLN) is expected to reach an average price of $7.5471 in 2030, with a high forecast of $8.8443 and a low forecast of $6.25. This signifies an +15.93% surge from the last price of $6.51.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $7.8684 | $6.25 | $8.45 | +20.87% |
| February, 2030 | $7.5801 | $7.1667 | $8.09 | +16.44% |
| March, 2030 | $7.7668 | $7.5318 | $8.5418 | +19.31% |
| April, 2030 | $7.9686 | $6.35 | $8.55 | +22.41% |
| May, 2030 | $7.6808 | $7.2672 | $8.1904 | +17.98% |
| June, 2030 | $7.868 | $7.6326 | $8.6426 | +20.86% |
| July, 2030 | $8.0688 | $6.45 | $8.65 | +23.95% |
| August, 2030 | $7.7815 | $7.3677 | $8.2908 | +19.53% |
| September, 2030 | $8.2511 | $7.7334 | $8.7434 | +26.75% |
| October, 2030 | $8.1691 | $6.55 | $8.75 | +25.49% |
| November, 2030 | $7.8822 | $7.4682 | $8.3911 | +21.08% |
| December, 2030 | $8.3524 | $7.8343 | $8.8443 | +28.30% |
3.26%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):